Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. SPY
4. META
5. MU
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Soligenix, Inc. (NASDAQ: SNGX) Delayed: 0.39 --0 (-0%)
Previous Close $0.39    52 Week High $4.35 
Open $0.39    52 Week Low $0.44 
Day High $0.41    P/E N/A 
Day Low $0.38    EPS $-0.81 
Volume 697,952